Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
60,558,345
-
Total 13F shares
-
24,743,225
-
Share change
-
+24,743,225
-
Total reported value
-
$614,460,000
-
Price per share
-
$24.95
-
Number of holders
-
29
-
Value change
-
+$614,460,000
-
Number of buys
-
29
Institutional Holders of Janux Therapeutics, Inc. - COMMON STOCK (JANX) as of Q2 2021
As of 30 Jun 2021,
Janux Therapeutics, Inc. - COMMON STOCK (JANX) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,743,225 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, JANUS HENDERSON GROUP PLC, CITADEL ADVISORS LLC, FMR LLC, EcoR1 Capital, LLC, BVF INC/IL, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Samsara BioCapital, LLC, and Logos Global Management LP.
This page lists
29
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.